Substituted piperidines

ABSTRACT

The present invention provides compounds having formula (II):  
                 
         wherein X, n, R 1 -R 12  are defined herein, or a pharmaceutically acceptable salt thereof. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound represented by formula (II) and a pharmaceutically acceptable carrier or excipient. The invention further provides a method for treating cancer comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound represented by formula (II).

PRIORITY TO RELATED APPLICATIONS

This application is a Division of Ser. No. 10/793,296, filed Mar. 4,2004, which is now allowed. This application claims the benefit of U.S.Provisional Application(s) Ser. No. 60/454,387, filed on Mar. 13, 2003.

FIELD OF THE INVENTION

The present invention provides a novel series of piperidines withcis-3,4-dialkoxy substitutions that are small molecule inhibitors ofMDM2-p53 interaction. These compounds are useful in the treatment orcontrol of cancer.

BACKGROUND OF THE INVENTION

-   -   p53 is a tumor suppresser protein that plays a central role in        protection against the development of cancer. p53 guards        cellular integrity and prevents the propagation of permanently        damaged clones of cells by the induction of growth arrest or        apoptosis. At the molecular level, p53 is a transcription factor        that can activate a panel of genes implicated in the regulation        of cell cycle and apoptosis. p53 is a potent cell cycle        inhibitor, which is tightly regulated by MDM2 at the cellular        level. MDM2 and p53 form a feedback control loop. MDM2 can bind        p53 and inhibit its ability to transactivate p53-regulated        genes. In addition, MDM2 mediates the ubiquitin-dependent        degradation of p53. p53 can activate the expression of the MDM2        gene, thus raising the cellular level of MDM2 protein. This        feedback control loop insures that both MDM2 and p53 are kept at        a low level in normal proliferating cells. MDM2 is also a        cofactor for E2F, which plays a central role in cell cycle        regulation.

The ratio of MDM2 to p53 (E2F) is dysregulated in many cancers.Frequently occurring molecular defects in the p16INK4/p19ARF locus, forinstance, have been shown to affect MDM2 protein degradation. Inhibitionof MDM2-p53 interaction in tumor cells with wild-type p53 should lead toaccumulation of p53, cell cycle arrest and/or apoptosis. MDM2antagonists, therefore, can offer a novel approach to cancer therapy assingle agents or in combination with a broad spectrum of other antitumortherapies. The feasibility of this strategy has been shown by the use ofdifferent macromolecular tools for inhibition of MDM2-p53 interaction(e.g. antibodies, antisense oligonucleotides, peptides). MDM2 also bindsE2F through a conserved binding region as p53 and activatesE2F-dependent transcription of cyclin A, suggesting that MDM2antagonists might have effects in p53 mutant cells.

SUMMARY OF THE INVENTION

The present invention provides a compound represented by formula (I):

wherein

-   n is an integer independently selected from 1 or 2;-   X is halogen;-   R₁ is selected from the group consisting of hydrogen, carbonyl,    sulfonyl, lower alkyl, and lower alkyl substituted by carbonyl,    sulfonyl, or hydroxy;-   R₂-R₆ are independently selected from the group consisting of    hydrogen, halogen, lower alkyl, —C(CH₃)₃, CF₃, —OCH₃, —NO₂, and —CN;    and-   R₇-R₁₁ are independently selected from the group consisting of    hydrogen, halogen, —CN, —NO₂, CF₃, —OCH₃, —COOCH₃, and —C₆H₅;    or a pharmaceutically acceptable salt thereof.

The present invention also provides a compound represented by formula(II):

wherein

-   n is an integer from 1 to 2;-   X is halogen;-   R₁ is selected from the group consisting of hydrogen, carbonyl,    sulfonyl, lower alkyl, and lower alkyl substituted by carbonyl,    sulfonyl, or hydroxy; and-   R₁₂ is selected from the group consisting of alkyl and alkenyl    having from 1 to about 5 carbon atoms;    or a pharmaceutically acceptable salt thereof.

The invention also provides a pharmaceutical composition comprising atherapeutically effective amount of a compound represented by formula(I) or (II) and a pharmaceutically acceptable carrier or excipient. Theinvention further provides a method for treating cancer comprisingadministering to a patient in need of such treatment a therapeuticallyeffective amount of a compound represented by formula (I) or (II).

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a novel series of small moleculeinhibitors of MDM2-p53 interaction, piperidines with cis-3,4-dialkoxysubstitutions, which have been tested in ELISA assays. The most potentcompounds in this series have been shown to inhibit interaction of MDM2protein with a p53-like peptide with a potency that is approximately thesame as a p53-derived peptide. Binding of these compounds to thep53-binding pocket of MDM2 protein has been confirmed by NMR studies ofselected compounds in this series as well as fragments of thesecompounds. These compounds have been shown to bind the same bindingpockets as cis-imidazolines, which have demonstrated clear mechanisticactivity in cell-based assays as well as antiproliferative activityagainst wild-type-p53 containing tumor cells both in vitro and in vivo.Therefore these compounds are useful as anticancer agents.

As used herein, the following terms have the given meanings:

“Alkenyl” means a straight-chain or branched aliphatic hydrocarbonhaving from 2 to 10, preferably 2 to 6 carbon atoms, and at least onecarbon-carbon double bond, for example, vinyl, 2-butenyl, and3-methyl-2-butenyl.

“Carbonyl” means a divalent —CO— radical.

“Effective amount” means an amount that is effective to prevent,alleviate or ameliorate symptoms of disease or prolong the survival ofthe subject being treated.

“Halogen” means fluorine, chlorine, bromine, or iodine.

“Hydroxy” means a monovalent —OH group.

“IC₅₀” means a concentration of a particular compound required toinhibit 50% of a specific measured activity. IC₅₀ can be measured, interalia, as is described subsequently.

“Lower alkyl group” means a straight-chained or branched saturatedaliphatic hydrocarbon. Typical lower alkyl groups include methyl, ethyl,propyl, and isopropyl.

“Pharmaceutically acceptable salt” refers to conventional acid-additionsalts or base-addition salts that retain the biological effectivenessand properties of the compounds of the present invention and are formedfrom suitable non-toxic organic or inorganic acids or organic orinorganic bases. Sample acid-addition salts include those derived frominorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodicacid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, andthose derived from organic acids such as p-toluenesulfonic acid,salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citricacid, malic acid, lactic acid, fumaric acid, and the like. Samplebase-addition salts include those derived from ammonium, potassium,sodium and, quaternary ammonium hydroxides, such as for example,tetramethylammonium hydroxide. Chemical modification of a pharmaceuticalcompound (i.e. drug) into a salt is a technique well known topharmaceutical chemists to obtain improved physical and chemicalstability, hygroscopicity, flowability and solubility of compounds. See,e.g., H. Ansel et. al., Pharmaceutical Dosage Forms and Drug DeliverySystems (6th Ed. 1995) at pp. 196 and 1456-1457.

“Pharmaceutically acceptable,” such as pharmaceutically acceptablecarrier, excipient, etc., means pharmacologically acceptable andsubstantially non-toxic to the subject to which the particular compoundis administered.

“Substituted,” as in substituted alkyl, means that the substitution canoccur at one or more positions and, unless otherwise indicated, that thesubstituents at each substitution site are independently selected fromthe specified options.

“Sulfonyl” means the bivalent radical —SO₂—.

“Therapeutically effective amount” means an amount of at least onecompound of formula (I) or (II), or a pharmaceutically acceptable saltthereof, which significantly inhibits proliferation and/or preventsdifferentiation of a human tumor cell, including human tumor cell lines.

Compounds of the present invention as exemplified advantageously showIC₅₀ values from about 3 μM to about 100 μM.

The compounds of the present invention are useful in the treatment orcontrol of cell proliferative disorders, in particular, oncologicaldisorders. These compounds and formulations containing the compounds maybe useful in the treatment or control of solid tumors, such as, forexample, breast, colon, lung and prostate tumors.

A therapeutically effective amount of a compound in accordance with thisinvention means an amount of compound that is effective to prevent,alleviate or ameliorate symptoms of disease or prolong the survival ofthe subject being treated. Determination of a therapeutically effectiveamount is within the skill in the art.

The therapeutically effective amount or dosage of a compound accordingto this invention can vary within wide limits and may be determined in amanner known in the art. Such dosage will be adjusted to the individualrequirements in each particular case including the specific compound(s)being administered, the route of administration, the condition beingtreated, as well as the patient being treated. In general, in the caseof oral or parenteral administration to adult humans weighingapproximately 70 Kg, a daily dosage of about 10 mg to about 10,000 mg,preferably from about 200 mg to about 1,000 mg, should be appropriate,although the upper limit may be exceeded when indicated. The dailydosage can be administered as a single dose or in divided doses, or forparenteral administration, it may be given as continuous infusion.

In accordance with the present invention, a compound is providedrepresented by formula (I):

wherein

-   n is an integer independently selected from 1 or 2;-   X is halogen;-   R₁ is selected from the group consisting of hydrogen, carbonyl,    sulfonyl, lower alkyl, and lower alkyl substituted by carbonyl,    sulfonyl, or hydroxy;-   R₂-R₆ are independently selected from the group consisting of    hydrogen, halogen, lower alkyl, —C(CH₃)₃, CF₃, —OCH₃, —NO₂, and —CN;    and-   R₇-R₁₁ are independently selected from the group consisting of    hydrogen, halogen, —CN, —NO₂, CF₃, —OCH₃, —COOCH₃, and —C₆H₅;    or a pharmaceutically acceptable salt thereof.

In a preferred embodiment of the invention, n is 1.

In another preferred embodiment of the invention, X is chloro or fluoro;more preferably chloro. In another preferred embodiment of theinvention, X is a para substituent.

In another preferred embodiment of the invention, R₁ is selected fromthe group consisting of hydrogen, —CH₂CH₃, —CH₂CH₂CH₃, —COCH₃,—COCH₂CH₃, —CH₂CHOHCH₂OH, and —SO₂CH₃; more preferably R₁ is hydrogen.

In another preferred embodiment of the invention, R₂ and R₆ areindependently selected from the group consisting of hydrogen andhalogen; more preferably hydrogen, fluoro, chloro, and bromo.

In another preferred embodiment of the invention, R₃ and R₅ areindependently selected from the group consisting of hydrogen, fluoro,chloro, bromo, —CH₃, —OCH₃, —CN, and —NO₂; more preferably R₃ and R₅ areindependently selected from the group consisting of hydrogen, fluoro,chloro, and bromo.

In another preferred embodiment of the invention, R₄ is selected fromthe group consisting of hydrogen, fluoro, chloro, bromo, —C(CH₃)₃, —CH₃,—CN, and —CF₃; more preferably R₄ is selected from the group consistingof hydrogen, fluoro, chloro, and bromo.

In another preferred embodiment of the invention, R₇ and R₁ areindependently selected from the group consisting of hydrogen, halogen,—CN, —NO₂, and —C₆H₅; more preferably R₇ and R₁₁ are independentlyselected from the group consisting of hydrogen, fluoro, chloro, andbromo.

In another preferred embodiment of the invention, R₈ and R₁₀ areindependently selected from the group consisting of hydrogen, fluoro,chloro, bromo, —CN, —NO₂, and —OCH₃; more preferably R₈ and R₁₀ areindependently selected from the group consisting of hydrogen, fluoro,chloro, and bromo.

In another preferred embodiment of the invention, R₉ is selected fromthe group consisting of hydrogen, fluoro, chloro, bromo, —OCH₃, —CN,—CF₃, and —COOCH₃; more preferably R₉ is selected from the groupconsisting of hydrogen, fluoro, chloro, and bromo.

Preferred compounds having formula (I) include:

-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(3,4-difluoro-benzyloxy)-piperidine;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,6-difluoro-benzyloxy)-piperidine;-   cis-[rac]-4-Benzyloxy-3-(biphenyl-2-ylmethoxy)-4-(4-chloro-phenyl)-piperidine;-   cis-[rac]-4-[4-Benzyloxy-4-(4-chloro-phenyl)-piperidin-3-yloxymethyl]-benzonitrile;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(3-nitro-benzyloxy)-piperidine;-   cis-[rac]-4-Benzyloxy-3-(3-bromo-benzyloxy)-4-(4-chloro-phenyl)-piperidine;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,4-difluoro-benzyloxy)-piperidine;-   cis-[rac]-4-Benzyloxy-3-(2-chloro-4-fluoro-benzyloxy)-4-(4-chloro-phenyl)-piperidine;-   cis-[rac]-4-[4-Benzyloxy-4-(4-chloro-phenyl)-piperidin-3-yloxymethyl]-benzoic    acid methyl ester;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(3,5-difluoro-benzyloxy)-piperidine;-   cis-[rac]-4-Benzyloxy-3-(3-chloro-2-fluoro-benzyloxy)-4-(4-chloro-phenyl)-piperidine;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,5-dichloro-benzyloxy)-piperidine;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,3-difluoro-benzyloxy)-piperidine;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(4-trifluoromethyl-benzyloxy)-piperidine;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(4-fluoro-benzyloxy)-piperidine;-   cis-[rac]-4-Benzyloxy-3-(4-bromo-benzyloxy)-4-(4-chloro-phenyl)-piperidine;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(3-fluoro-benzyloxy)-piperidine;-   cis-[rac]-2-[4-Benzyloxy-4-(4-chloro-phenyl)-piperidin-3-yloxymethyl]-benzonitrile;-   cis-[rac]-3-[4-Benzyloxy-4-(4-chloro-phenyl)-piperidin-3-yloxymethyl]-benzonitrile;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(4,5-dimethoxy-2-nitro-benzyloxy)-piperidine;-   cis-[rac]-4-Benzyloxy-3-but-2-enyloxy-4-(4-chloro-phenyl)-piperidine;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-pent-2-enyloxy-piperidine;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,3,6-trifluoro-benzyloxy)-piperidine;-   cis-[rac]-4-Benzyloxy-3-butoxy-4-(4-chloro-phenyl)-piperidine;-   cis-[rac]-4-Benzyloxy-3-(4-chloro-2-fluoro-benzyloxy)-4-(4-chloro-phenyl)-piperidine;-   cis-[rac]-4-Benzyloxy-3-(4-bromo-2-fluoro-benzyloxy)-4-(4-chloro-phenyl)-piperidine;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,4,6-trifluoro-benzyloxy)-piperidine;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,4,5-trifluoro-benzyloxy)-piperidine;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,3,4-trifluoro-benzyloxy)-piperidine;-   cis-[rac]-3-Benzyloxy-4-(4-chloro-phenyl)-4-(2,4,6-trifluoro-benzyloxy)-piperidine;-   cis-[rac]-3-Benzyloxy-4-(4-chloro-phenyl)-4-(2,5-dichloro-benzyloxy)-piperidine;-   cis-[rac]-3-Benzyloxy-4-(4-chloro-phenyl)-4-(2,6-dichloro-benzyloxy)-piperidine;-   cis-[rac]-3-Benzyloxy-4-(4-chloro-phenyl)-4-(2,6-difluoro-benzyloxy)-piperidine;-   cis-[rac]-3-Benzyloxy-4-(4-chloro-phenyl)-4-(3-methoxy-benzyloxy)-piperidine;-   cis-[rac]-3-Benzyloxy-4-(4-chloro-phenyl)-4-(2,3,6-trifluoro-benzyloxy)-piperidine;-   cis-[rac]-3-Benzyloxy-4-(4-chloro-phenyl)-4-(2-fluoro-benzyloxy)-piperidine;-   cis-[rac]-3-Benzyloxy-4-(4-chloro-phenyl)-4-(2-fluoro-3-methyl-benzyloxy)-piperidine;-   cis-[rac]-4-(4-Chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-4-(4-fluoro-benzyloxy)-piperidine;-   cis-[rac]-4-(4-Bromo-benzyloxy)-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-piperidine;-   cis-[rac]-4-(4-Chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-4-(2,4-difluoro-benzyloxy)-piperidine;-   cis-[rac]-4-(2-Chloro-4-fluoro-benzyloxy)-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-piperidine;-   cis-[rac]-4-(2-Bromo-benzyloxy)-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-piperidine;-   cis-[rac]-4-(4-tert-Butyl-benzyloxy)-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-piperidine;-   cis-[rac]-4-[4-(4-Chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-piperidin-4-yloxymethyl]-benzonitrile;-   cis-[rac]-4-(3-Chloro-benzyloxy)-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-piperidine;-   cis-[rac]-4-(3-Bromo-benzyloxy)-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-piperidine;-   cis-[rac]-4-(4-Chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-4-(2-fluoro-benzyloxy)-piperidine;-   cis-[rac]-4-(4-Chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-4-(3,5-difluoro-benzyloxy)-piperidine;-   cis-[rac]-4-(3-Chloro-2-fluoro-benzyloxy)-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-piperidine;-   cis-[rac]-4-(4-Chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-4-(2,3-difluoro-benzyloxy)-piperidine;-   cis-[rac]-4-(4-Chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-4-(4-trifluoromethyl-benzyloxy)-piperidine;-   cis-[rac]-4-(4-Chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-4-(3-fluoro-benzyloxy)-piperidine;-   cis-[rac]-3-[4-(4-Chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-piperidin-4-yloxymethyl]-benzonitrile;-   cis-[rac]-4-(2-Chloro-benzyloxy)-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-piperidine;-   cis-[rac]-4-(4-Chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-4-(4-methyl-benzyloxy)-piperidine;-   cis-[rac]-4-(4-Chloro-phenyl)-3,4-bis-(2,4-difluoro-benzyloxy)-piperidine;-   cis-[rac]-4-(4-Chloro-phenyl)-3,4-bis-(3-nitro-benzyloxy)-piperidine;-   cis-[rac]-1-[4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,4-difluoro-benzyloxy)-piperidin-1-yl]-ethanone;-   cis-[rac]-1-[4-Benzyloxy-3-(3-bromo-benzyloxy)-4-(4-chloro-phenyl)-piperidin-1-yl]-ethanone;-   cis-[rac]-1-[4-Benzyloxy-3-(2-chloro-4-fluoro-benzyloxy)-4-(4-chloro-phenyl)-piperidin-1-yl]-ethanone;-   cis-[rac]-1-[4-Benzyloxy-4-(4-chloro-phenyl)-3-(3,5-difluoro-benzyloxy)-piperidin-1-yl]-ethanone;-   cis-[rac]-1-[4-Benzyloxy-3-(3-chloro-2-fluoro-benzyloxy)-4-(4-chloro-phenyl)-piperidin-1-yl]-ethanone;-   cis-[rac]-1-[4-Benzyloxy-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-piperidin-1-yl]-ethanone;-   cis-[rac]-1-[4-Benzyloxy-4-(4-chloro-phenyl)-3-(4-fluoro-benzyloxy)-piperidin-1-yl]-ethanone;-   cis-[rac]-1-[4-Benzyloxy-3-(4-bromo-benzyloxy)-4-(4-chloro-phenyl)-piperidin-1-yl]-ethanone;-   cis-[rac]-1-[4-Benzyloxy-4-(4-chloro-phenyl)-3-(3-fluoro-benzyloxy)-piperidin-1-yl]-ethanone;-   cis-[rac]-3-[1-Acetyl-4-benzyloxy-4-(4-chloro-phenyl)-piperidin-3-yloxymethyl]-benzonitrile;-   cis-[rac]-1-[4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,6-difluoro-benzyloxy)-piperidin-1-yl]-ethanone;-   cis-[rac]-1-[4-Benzyloxy-4-(4-chloro-phenyl)-3-(3-nitro-benzyloxy)-piperidin-1-yl]-ethanone;-   cis-[rac]-1-[4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,3,4-trifluoro-benzyloxy)-piperidin-1-yl]-ethanone;-   cis-[rac]-1-[4-(4-Chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-4-(2-fluoro-benzyloxy)-piperidin-1-yl]-ethanone;-   cis-[rac]-1-[4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,3,4-trifluoro-benzyloxy)-piperidin-1-yl]-propan-1-one;-   cis-[rac]-1-[4-Benzyloxy-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-piperidin-1-yl]-propan-1-one;-   cis-[rac]-4-Benzyloxy-3-(4-bromo-benzyloxy)-4-(4-fluoro-phenyl)-piperidine;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-1-ethyl-piperidine;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-1-propyl-piperidine;-   cis-[rac]-3-[4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,3,4-trifluoro-benzyloxy)-piperidin-1-yl]-propane-1,2-diol;-   cis-[rac]-3-[4-Benzyloxy-3-(4-bromo-benzyloxy)-4-(4-chloro-phenyl)-piperidin-1-yl]-propane-1,2-diol;    and-   cis-[rac]-3-[4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,3,4-trifluoro-benzyloxy)-piperidin-1-yl]-methane    sulfonyl.

Further in accordance with the present invention, a compound is providedhaving formula (II):

wherein

-   n is an integer from 1 to 2;-   X is halogen;-   R₁ is selected from the group consisting of hydrogen, carbonyl,    sulfonyl, lower alkyl, and lower alkyl substituted by carbonyl,    sulfonyl, or hydroxy; and-   R₁₂ is selected from the group consisting of alkyl and alkenyl    having from 1 to about 5 carbon atoms;    or a pharmaceutically acceptable salt thereof.

In a preferred embodiment of the invention, n is 1.

In another preferred embodiment of the invention, X is chloro or fluoro;more preferably chloro. In another preferred embodiment of theinvention, X is a para substituent.

In another preferred embodiment of the invention, R₁ is selected fromthe group consisting of hydrogen, —CH₂CH₃, —CH₂CH₂CH₃, —COCH₃,—COCH₂CH₃, —CH₂CHOHCH₂OH, and —SO₂CH₃; more preferably R₁ is hydrogen.

In another preferred embodiment of the invention, R₁₂ is selected fromthe group consisting of —(CH₂)₃CH₃, —(CH₂)₄CH₃, —CH₂CH═CHCH₃, and—CH₂CH═CH CH₂CH₃.

Preferred compounds having formula (II) include:

-   cis-[rac]-4-Benzyloxy-4-(4-fluoro-phenyl)-3-butyloxy-piperidine;-   cis-[rac]-4-Benzyloxy-4-(4-fluoro-phenyl)-3-pentyloxy-piperidine;-   cis-[rac]-4-Benzyloxy-4-(4-fluoro-phenyl)-3-(but-2-en)yloxy-piperidine;    and-   cis-[rac]-4-Benzyloxy-4-(4-fluoro-phenyl)-3-(pent-2-enyl)oxy-piperidine.

Other preferred compounds having formula (II) include:

-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-butyloxy-piperidine;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-pentyloxy-piperidine;-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(but-2-en)yloxy-piperidine;    and-   cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(pent-2-enyl)oxy-piperidine.

The invention also provides a pharmaceutical composition comprising atherapeutically effective amount of a compound represented by formula(I) or (II) and a pharmaceutically acceptable carrier or excipient. Theinvention further provides a method for treating cancer comprisingadministering to a patient in need of such treatment a therapeuticallyeffective amount of a compound represented by formula (I) or (II).Preferably, the cancer is breast or colon cancer.

The compounds of the present invention, and intermediates thereof, canbe prepared according to the schemes set out below. Starting materialsare made using known procedures or as illustrated. The abbreviationsused in the descriptions of the schemes, preparations, and the examplesare set out below.

-   ACE-Cl=1-chloroethyl chloroformate (Aldrich)-   BEMP=2-tert-butylimino-2-diethylamino-1,3-dimethyl-perhydro-1,3,2-diazaphosphorine    (Fluka)-   Boc=tert-butyloxycarbonyl-   t-BuOK=potassium tert-butoxide-   CH₂Cl₂=dichloromethane-   DCE=1,2-dichloroethane-   DMF=N,N-dimethylformamide-   Et₂O=diethyl ether-   EtOH=ethanol-   H₂SO₄=sulfuric acid-   HCl=hydrogen chloride-   H₂O=water-   MeOH=methanol-   NaH=sodium hydride-   NMO=N-methylmorpholine-N-oxide-   NMP=1-methyl-2-pyrrolidinone-   OSO₄ osmium tetroxide-   Polymer (supported)    BEMP=2-tert-butylimino-2-diethylamino-1,3-dimethyl-perhydro-1,3,2-diazaphosphorine    supported by polystyrene resin (Fluka)-   i-Pr₂NEt=N,N-diisopropylethylamine-   TEA=triethylamine-   TFA=trifluoroacetic acid-   THF=tetrahydrofuran

Schemes 1-3 outline a general method for preparing compounds of theinvention having formula (I) and (II) using a novel solid phasesynthesis. Scheme 4 outlines a general method for preparing thecompounds in solution phase. Scheme 5 illustrates various methods formodifying the R₁ group using a novel polymer supported reagent.

In Scheme 1, the protection of a secondary amine of a commerciallyavailable 4-aryl-1,2,3,6-tetrahydropyridine is outlined. The preferredprotecting group is a tert-butyloxycarbonyl, which can be synthesizedfrom known procedures (Greene, T. W. and Wuts, P. G. M, 2^(nd) Edition,John Wiley & Sons, N.Y. 1991). For liquid phase synthesis, the resultingtert-butyl ester can be treated with OsO₄/NMO to form the dihydroxyintermediate A. Selective o-alkylation of intermediate A at C3 can becarried out using NaH and 4-methoxybenzyl chloride. The resultingintermediate can be benzylated according to known methods. Deprotectionof both 4-methoxylbenzyl and tert-butyloxycarbonyl groups using 50%TFA/CH₂Cl₂ yields 4-aryl-4-benzyloxy-3-hydroxypiperidine B. For solidphase synthesis, the resulting piperidine B can be coupled to a suitablelinker, such as a chloromethyl derivative ArgoPore-Cl linker (Argonaut).Alkylation on solid phase can be accomplished using t-BuOK to generatethe anion followed by coupling with various alkyl halides (RX). Thefinal reaction product can be cleaved from the N-benzyl linked tertiaryamine linker using alpha-chloroethyl chloroformat (ACE-Cl)/MeOH to givethe piperidine compounds of the invention (Leysen, D. et al. TetrahedronLett. 1997, 2915-2918).

In Scheme 2, a general method is outlined for preparing compounds offormula (I) that feature functionalized R groups derived fromintermediate A in Scheme 1. Intermediate A can be converted to4-aryl-3-benzyloxy-3-hydroxypiperidine via alkylation at C3 using NaHand benzylbromide followed by acidic deprotection of atert-butyloxycarbonyl group. The subsequent synthesis on solid phase canbe accomplished to yield the piperidine compounds of the inventionfollowing the described reactions set out in Scheme 1.

In Scheme 3, deprotection of a tert-butyloxycarbonyl from intermediate Acan be carried out using 50% TFA/CH₂Cl₂. The synthesis on solid phasecommences with the coupling of the resulting4-aryl-3,4-dihydroxypiperidine with a ArgoPore-Cl linker. Dialkylationusing t-BuOK and alkyl halides (RX) followed by cleavage of the polymersupport according to the described conditions affords the piperidinecompounds of the invention.

In Scheme 4, a general synthetic method is outlined for preparingcompounds of formula (I) and (II) in solution phase. Sequentialalkylation of intermediate A using NaH and alkyl halides followed byacidic deprotection of tert-butyloxycarbonyl provides the piperidinecompounds of the invention.

In Scheme 5, a general method is outlined for the post-modification ofintermediate C. The secondary amine of intermediate C can be treatedwith a variety of agents such as acyl chlorides, alkyl halides, andsulfonyl chlorides to form the corresponding amide, tert-amine, orsulfonamide. The intermediate C can also be allylated using polymersupport BEMP and allyl iodide to form the N-allyl substitutedintermediate, which can be further treated with OsO₄/NMO to form3-propane-1,2-diol-substituted piperidines of the invention.

The compounds of the present invention can be prepared according to theexamples below. The examples are presented for purposes ofdemonstrating, but not limiting, the preparation of the compounds andcompositions of this invention.

EXAMPLES

The inhibitory activity (IC₅₀) of the compounds prepared in the examplesbelow, and represented by formula (I) or (II), is in the range of 3 μMto 100 μM.

Example 1cis-[rac]-4-(4-Chlorophenyl)-3,4-dihydroxypiperidine-1-carboxylic AcidTert-Butyl Ester

4-(4-Chlorophenyl)-1,2,3,6-tetrahydropyridine hydrochloride (Lancaster,1.00 g, 4.35 mmol), triethylamine (0.92 g, 9.13 mmol), and di-tert-butylcarbonate (Aldrich, 1.04 g, 4.78 mmol) were combined in dichloromethane(100 mL) and stirred at room temperature for 14 hours. The mixture waswashed with saturated aqueous ammonium chloride solution (30 mL), water(30 mL), saturated sodium chloride solution (30 mL) and dried overanhydrous magnesium sulfate. The mixture was filtered and concentratedin vacuo to give 4-(4-chlorophenyl)-3,6-dihydro-2H-pyridine-1-carboxylicacid tert-butyl ester (1.41 g, 100%) of as a viscous yellow oil, whichwas used without further purification.4-(4-Chlorophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butylester (334 mg, 1.14 mmoL) was dissolved in acetone/water (1:1, 10 mL),and N-methylmorpholine-N-oxide (Aldrich, 462 mg, 3.42 mmoL) and acatalytic amount of osmium tetroxide (Aldrich) were added. The mixturewas stirred at room temperature for 3 hours. A saturated aqueoussolution of sodium sulfite (2 mL) was added, and the mixture was stirredfor 30 minutes at room temperature. The mixture was diluted with ethylacetate (10 mL) and water (5 mL). The organic layer was separated, andthe aqueous layer was extracted with ethyl acetate (2×10 mL). Thecombined organic layers were washed with brine and dried over anhydrousmagnesium sulfate. The mixture was filtered and concentrated in vacuo togive cis-[rac]-4-(4-chlorophenyl)-3,4-dihydroxypiperidine-1-carboxylicacid tert-butyl ester (364 mg, 1.11 mmol, 97%) as a yellow oil.

Example 2cis-[rac]-4-(4-Chlorophenyl)-3-(3,4-dichlorobenzyloxy)-4-hydroxypiperidine-1-carboxylicAcid Tert-Butyl Ester

To an ice-cold suspension of sodium hydride (62 mg, 2.6 mmoL) in amixture of tetrahydrofuran/N,N-dimethylformamide (4/1, 4 mL) was addeddropwise a solution ofcis-[rac]-4-(4-chlorophenyl)-3,4-dihydroxypiperidine-1-carboxylic acidtert-butyl ester (Example 1, 340 mg, 1.04 mmol) intetrahydrofuran/N,N-dimethylformamide (1 mL, 4/1). After the additionwas complete, the mixture was stirred with ice cooling for 15 minutes.Then 3,4-dichlorobenzyl chloride (Aldrich, 239 mg, 1.14 mmol) was added,and the mixture was warmed to room temperature and stirred for 20 hours.The mixture was poured into a saturated aqueous solution of ammoniumchloride (30 mL), and the mixture was extracted with ethyl acetate (3×15mL). The combined organic layers were washed with water (2×20 mL),saturated aqueous sodium chloride solution (1×20 mL), and dried overanhydrous magnesium sulfate. The mixture was filtered and concentratedin vacuo to give a viscous oil (500 mg), which was purified by flashsilica gel chromatography (Merck silica gel 60, 230 to 400 mesh) toaffordcis-[rac]-4-(4-chlorophenyl)-3-(3,4-dichlorobenzyloxy)-4-hydroxypiperidine-1-carboxylicacid tert-butyl ester (310 mg, 61%) as a colorless oil.

Example 3cis-[rac]-4-(Benzyloxy)-4-(4-chlorophenyl)-3-(3,4-dichlorobenzyloxy)-piperidine-1-carboxylicAcid Tert-Butyl Ester

To an ice cold solution ofcis-[rac]-4-(4-chlorophenyl)-3-(3,4-dichloro-benzyloxy)-4-hydroxypiperidine-1-carboxylicacid tert-butyl ester (Example 2, 224 mg, 0.46 mmol) in tetrahydrofuran(1.5 mL) was added sodium hydride (22 mg, 0.92 mmol) portionwise. Afterstirring with ice cooling for ten minutes, benzyl bromide (86 mg, 0.51mmol) was added followed by N,N-dimethylformamide (0.5 mL). The coolingbath was removed, and the mixture was warmed to room temperature andstirred for 3 hours. Several drops of methanol were added, and themixture was stirred and room temperature for 1 hour. The mixture waspartitioned between ethyl acetate (30 mL) and saturated aqueous ammoniumchloride solution (15 mL). The organic layer was separated, and theaqueous layer was extracted with ethyl acetate (3×15 mL). The combinedorganic layers were washed with water (3×30 mL), saturated aqueoussodium chloride solution (15 mL) and dried over anhydrous magnesiumsulfate. The mixture was filtered and concentrated in vacuo to givecis-[rac]-4-(benzyloxy)-4-(4-chlorophenyl)-3-(3,4-dichlorobenzyloxy)-piperidine-1-carboxylicacid tert-butyl ester (240 mg), which was used without furtherpurification.

Example 4cis-[rac]-4-(Benzyloxy)-4-(4-chlorophenyl)-3-(3,4-dichlorobenzyloxy)-piperidineHydrochloride

Crudecis-[rac]-4-(benzyloxy)-4-(4-chlorophenyl)-3-(3,4-dichlorobenzyloxy)-piperidine-1-carboxylicacid tert-butyl ester (Example 3, 240 mg) was dissolved in anhydrousdiethyl ether (10 mL). The mixture was cooled in an ice bath, andhydrogen chloride gas was passed through the solution for 10 minutes.The reaction vessel was tightly stoppered and stored at 0° C. for 24hours. The precipitated solid was collected and washed with diethylether to affordcis-[rac]-4-(benzyloxy)-4-(4-chlorophenyl)-3-(3,4-dichlorobenzyloxy)-piperidinehydrochloride as a white solid (130 mg, 55%). HR-FAB m/e calcd forC₂₄H₂₄NO₂Cl: [M+H]⁺ 476.0952, found 476.0931.

Example 5cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(4-methoxy-benzyloxy)-piperidine-1-carboxylicAcid Tert-Butyl Ester

cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(4-methoxy-benzyloxy)-piperidine-1-carboxylicacid tert-butyl ester was prepared fromcis-[rac]-4-(4-chlorophenyl)-3,4-dihydroxypiperidine-1-carboxylic acidtert-butyl ester (Example 1) and 4-methoxybenzyl chloride (Aldrich)following the procedures used in Examples 2 and 3, which was usedwithout purification.

Example 6 cis-[rac]-4,4-[benzyloxy-(4-chlorophenyl)]-3-hydroxypiperidine

cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(4-methoxy-benzyloxy)-piperidine-1-carboxylicacid tert-butyl ester (Example 5, 550 mg, 1.02 mmol) was dissolved in50% trifluoroacetic acid/dichloromethane (10 mL). After stirring 1.5hours, the solution was evaporated in vacuo. The residue was trituratedin 1:1 ethyl acetate/hexane to providecis-[rac]-4,4-[benzyloxy-(4-chlorophenyl)]-3-hydroxypiperidine (150 mg)as a white powder. Mass spectrum (ES) [M+CH₃CN]⁺=359.

Example 7 Resin-boundcis-[rac]-4,4-[benzyloxy-(4-chlorophenyl)]-3-hydroxypiperidine

A mixture ofcis-[rac]-4,4-[benzyloxy-(4-chlorophenyl)]-3-hydroxypiperidine (Example6, 7.3 g, 23 mmol), ArgoPore-Cl resin (16 g, 15.3 mmol, loadingcapacity: 0.96 mmol from Argonaut Inc.), and N,N-diisopropylethylamine(13 mL, 76.7 mmol) in N-methylpyrrolinone (12 mL) was heated at 60° C.overnight. The resin was filtered and washed successively with CH₂Cl₂,and MeOH. The resin was dried at 4⁰° C./high vacuum overnight to provideresin-bound 4,4-[benzyloxy-(4-chlorophenyl)]-3-hydroxypiperidine.

Example 8 cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-substitutedPiperidine Library

General Procedure

To a suspension of resin-boundcis-[rac]-4,4-[benzyloxy-(4-chlorophenyl)]-3-hydroxypiperidine (Example7, 200 mg, 0.192 mmol, loading capacity: 0.96 mmol/g) and alkyl halide(RX, 0.58 mmol) in 4:1 THF:DMF solution (2 mL) was added potassiumt-butoxide (0.77 M in THF; 1 mL, 0.77 mmol). After stirring at roomtemperature overnight, the resin was filtered and washed successivelywith N,N-dimethylformamide, tetrahydrofuran, methanol, dichloromethane,and diethyl ether. The resin was dried at 40° C./high vacuum overnight.1-Chloroethyl chloroformate (0.2 mL, 1.9 mmol) was added to the resin in1,2-dichloroethane (2 mL). After shaking 4 hours at room temperature,the resin was filtered off and washed with 1,2-dichloroethane (3×2 mL).The filtrate was evaporated in vacuo. Dry methanol (2 mL) was added tothe residue and the solution was heated at 60° C. for 3 hours. Thesolution was evaporated in vacuo to provide the desired product.

In the manner described above, the following compounds were prepared.Starting Material: Mass Spectrum Example Alkyl halide (RX) ProductNomeclature (ES) 8A 3,4-DIFLUOROBENZYL BROMIDE (Aldrich)

4-Benzyloxy-4-(4-chloro- phenyl)-3-(3,4-difluoro- benzyloxy)-piperidine444 8B 2,6-DIFLUOROBENZYL BROMIDE

4-Benzoyloxy-4-(4-chloro- phenyl)-3-(2,6-difluoro- benzyloxy)-piperidine444 8C 2-PHENYLBENZYL BROMIDE (Aldrich)

4-Benzyloxy-3-(biphenyl-2- ylmethoxy)-4-(4-chloro- phenyl)-piperidine484 8D ALPHA-BROMO-P- TOLUENITRILE (Aldrich)

4-[4-Benzyloxy-4-(4-chloro- phenyl)-piperidin-3-yloxymethyl]-benzonitrile 433 8E 3-NITROBENZYL BROMIDE (Lancaster)

4-Benzoyloxy-4-(4-chloro- phenyl)-3-(3-nitro- benzyloxy)-piperidine 4538F 3-BROMOBENZYL BROMIDE (Aldrich)

4-Benzyloxy-3-(3-bromo- benzyloxy)-4-(4-chloro- phenyl)-piperidine 4878G 2,4-DIFLUOROBENZYL BROMIDE (Lancaster)

4-Benzyloxy-4-(4-chloro- phenyl)-3-(2,4-difluoro- benzyloxy)-piperidine444 8H 2-CHLORO-4- FLUOROBENZYL BROMIDE (Lancaster)

4-Benzyloxy-3-(2-chloro-4- fluoro-benzyloxy)-4-(4-chloro-phenyl)-piperidine 460 8I METHYL 4- (BROMOMETHYL) BENZOATE(Aldrich)

4-[4-Benzoyloxy-4-(4-chloro- phenyl)-piperidin-3- yloxymethyl]-benzoicacid methyl ester 466 8J 3,5-DIFLUOROBENZYL BROMIDE (Lancaster)

4-Benzyloxy-4-(4-chloro- phenyl)-3-(3,5-difluoro- benzyloxy)-piperidine444 8K 3-CHLORO-2- FLUOROBENZYL BROMIDE (Lancaster)

4-Benzyloxy-3-(3-chloro-2- fluoro-benzyloxy)-4-(4-chloro-phenyl)-piperidine 460 8L 2,5-DICHLOROBENZYL BROMIDE (Lancaster)

4-Benzyloxy-4-(4-chloro- phenyl)-3-(2,5-dicloro- benzyloxy)-piperidine477 8M 2,3-DIFLUOROBENZYL BROMIDE (Aldrich)

4-Benzyloxy-4-(4-chloro- phenyl)-3-(2,3-difluoro- benzyloxy)-piperidine444 8N 4-(TRIFLUORO- METHYL)BENZYL BROMIDE (Aldrich)

4-Benzyloxy-4-(4-chloro- phenyl)-3-(4-trifluoromethyl-benzyloxy)-piperidine 476 8O 4-FLUOROBENZYL BROMIDE (Aldrich)

4-Benzyloxy-4-(4-chloro- phenyl)-3-(4-fluoro- benzyloxy)-piperidine 4268P 4-BROMOBENZYL- BROMIDE (Aldrich)

4-Benzyloxy-3-(4-bromo- benzyloxy)-4-(4-chloro- phenyl)-piperidine 4878Q 3-FLUOROBENZYL- BROMIDE (Aldrich)

4-Benzyloxy-4-(4-chloro- phenyl)-3-(3-fluoro- benzyloxy)-piperidine 4268R ALPHA-BROMO-O- TOLUNITRILE (Aldrich)

2-[4-Benzyloxy-4-(4-chloro- phenyl)-piperidin-3-yloxymethyl]-benzonitrile 433 8S ALPHA-BROMO-M- TOLUNITRILE (Aldrich)

3-[4-Benzyloxy-4-(4-chloro- phenyl)-piperidin-3-yloxymethyl]-benzonitrile 433 8T 4,5-DIMETHOXY-2- NITROBENZYL BROMIDE(Aldrich)

4-Benzyloxy-4-(4-chloro- phenyl)-3-(4,5-dimethoxy-2-nitro-benzyloxy)-piperidine 513 8U CROTYL BROMIDE (Aldrich)

4-Benzyloxy-3-but-2- enyloxy-4-(4-chloro-phenyl)- piperidine 372 8V1-BROMO-2-PENTENE (Aldrich)

4-Benzyloxy-4-(4-chloro- phenyl)-3-pent-2-enyloxy- piperidine 386 8W2,3,6-TRIFLUORO- BENZYL BROMIDE (Aldrich)

4-Benzyloxy-4-(4-chloro- phenyl)-3-(2,3,6-trifluoro-benzyloxy)-piperidine 462 8X 1-IODOBUTANE (Aldrich)

4-Benzyloxy-3-butoxy-4-(4- chloro-phenyl)-piperidine 374 8Y 4-CHLORO-2-FLUOROBENZYL BROMIDE (Maybridge)

4-Benzyloxy-3-(4-chloro-2- fluoro-benzyloxy)-4-(4-chloro-phenyl)-piperidine 460 8Z 4-BROMO-2- FLUOROBENZYL BROMIDE(Aldrich)

4-Benzyloxy-3-(4-bromo-2- fluoro-benzyloxy)-4-(4-chloro-phenyl)-piperidine 505 8Aa 2,4,6-TRIFLUORO- BENZYL BROMIDE(Lancaster)

4-Benzyloxy-4-(4-chloro- phenyl)-3-(2,4,6-trifluoro-benzyloxy)-piperidine 462 8Ab 2,4,5-TRIFLUORO- BENZYL BROMIDE(Lancaster)

4-Benzyloxy-4-(4-chloro- phenyl)-3-(2,4,5-trifluoro-benzyloxy)-piperidine 462 8Ac 2,3,4-TRIFLUORO BENZYL BROMIDE (Lancaster)

4-Benzyloxy-4-(4-chloro- phenyl)-3-(2,3,4-trifluoro-benzyloxy)-piperidine 462

Example 9 cis-[rac]-3-benzyloxy-4,4-[(4-chlorophenyl)-hydroxy]piperidine

cis-[rac]-3-benzyloxy-4,4-[(4-chlorophenyl)-hydroxy]piperidine wasprepared fromcis-[rac]-4-(4-chlorophenyl)-3,4-dihydroxypiperidine-1-carboxylic acidtert-butyl ester (Example 1) and benzyl bromide (Aldrich) following theprocedure used in Examples 2 and 6.

Example 10 Resin-boundcis-[rac]-3-benzyloxy-4,4-[(4-chlorophenyl)-hydroxy]piperidine

This resin-bound compound was prepared fromcis-[rac]-3-benzyloxy-4,4-[(4-chlorophenyl)-hydroxy]piperidine (Example9) following the procedure used in Example 7.

Example 11 cis-[rac]-3-Benzyloxy-4-(4-chlorophenyl)-4-substitutedPiperidine Library

General Procedure

cis-[rac]-3-Benzyloxy-4-(4-chlorophenyl)-4-substituted piperidine wasprepared from resin-boundcis-[rac]-3-benzyloxy-4,4-[(4-chlorophenyl)-hydroxy]piperidine (Example10) and alkyl bromide following the procedure used in Example 8.

In the manner described above, the following compounds were prepared.Starting Material: Mass Spectrum Example Alkyl halide (RX) ProductNomeclature (ES) 11A 2,4,6-TRIFLUORO BENZYL BROMIDE (Lancaster)

3-Benzyloxy-4-(4-chloro- phenyl)-4-(2,4,6-trifluoro-benzyloxy)-piperidine 462 11B 2,5-DICHLOROBENZYL- BROMIDE (Lancaster)

3-Benzyloxy-4-(4-chloro- phenyl)-4-(2,5-dichloro- benzyloxy)-piperidine477 11C 2,6-DICHLOROBENZYL BROMIDE (Aldrich)

3-Benzyloxy-4-(4-chloro- phenyl)-4-(2,6-dichloro- benzyloxy)-piperidine477 11D 2,6-DIFLUOROBENZYL BROMIDE (Aldrich)

3-Benzyloxy-4-(4-chloro- phenyl)-4-(2,6-dfifluoro- benzyloxy)-piperidine444 11E 3-METHOXYBENZYL BROMIDE (Aldrich)

3-Benzyloxy-4-(4-chloro- phenyl)-4-(3-methoxy- benzyloxy)-piperidine 43811F 2,3,6-TRIFLUORO BENZYL BROMIDE (Aldrich)

3-Benzyloxy-4-(4-chloro- phenyl)-4-(2,3,6-trifluoro-benzyloxy)-piperidine 462 11G 2-FLUOROBENZYL BROMIDE (Aldrich)

3-Benzyloxy-4-(4-chloro- phenyl)-4-(2-fluoro- benzyloxy)-piperidine 42611H 2-FLUORO-3- METHYLBENZYL BROMIDE (Maybridge)

3-Benzyloxy-4-(4-chloro- phenyl)-4-(2-fluoro-34-methyl-benzyloxy)-piperidine 440

Example 12 Resin-bound3-(3,4-dichlorobenzyloxy)-4,4-[(4-chlorophenyl)-hydroxy]piperidine

This resin-bound compound was prepared following the procedure used inExamples 2, 6, and 7.

Example 13 4-(4-Chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-4-substitutedPiperidine

General Procedure

4-(4-Chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-4-substituted piperidinewas prepared from resin-bound3-(3,4-dichlorobenzyloxy)-4,4-[(4-chlorophenyl)-hydroxy]piperidine(Example 12) and alkyl bromide following the procedure used in Example8.

In the manner described above, the following compounds were prepared.Starting Material: Mass Spectrum Example Alkyl halide (RX) ProductNomeclature (ES) 13A 4-FLUOROBENZYL BROMIDE (Aldrich)

4-(4-Chloro-phenyl)-3-(3,4- dichloro-benzyloxy)-4-(4-fluoro-benzyloxy)-piperidine 496 13B 4-BROMOBENZYL BROMIDE (Aldrich)

4-(4-Bromo-benzyloxy)-4- (4-chloro-phenyl)-3-(3,4- dichloro-benzyloxy)-piperidine 556 13C 2,4- DIFLUOROBENZYL BROMIDE (Lancaster)

4-(4-Chloro-phenyl)-3-(3,4- dichloro-benzyloxy)-4-(2,4-difluoro-benzyloxy)- piperidine 514 13D 2-CHLORO-4- FLUOROBENZYLBRO MIDE(Lancaster)

4-(2-Chloro-4-fluoro- benzyloxy)-4-(4-chloro- phenyl)-3-(3,4-dichloro-benzyloxy)-piperidine 530 13E 2-BROMOBENZYL BROMIDE (Aldrich)

4-(2-Bromo-benzyloxy)-4- (4-chloro-phenyl)-3-(3,4- dichloro-benzyloxy)-piperidine 556 13F 4-(TERT- BUTYL)BENZYL BROMIDE (Fluka)

4-(4-tert-Butyl-benzyloxy)- 4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)- piperidine 533 13G ALPHA-BROMO-P- TOLUNITRILE(Aldrich)

4-[4-(4-Chloro-phenyl)-3- (3,4-dichloro-benzyloxy)-piperidin-4-yloxymeethyl]- benzonitrile 502 13H 3-CHLOROBENZYL BROMIDE(Aldrich)

4-(3-Chloro-benzyloxy)-4- (4-chloro-phenyl)-3-(3,4- dichloro-benzyloxy)-piperidine 512 13I 3-BROMOBENZYL BROMIDE (Aldrich)

4-(3-Bromo-benzyloxy)-4- (4-chloro-phenyl)-3-(3,4- dichloro-benzyloxy)-piperidine 556 13J 2-FLUOROBENZYL BROMIDE (Aldrich)

4-(4-Chloro-phenyl)-3-(3,4- dichloro-benzyloxy)-4-(2-fluoro-benzyloxy)-piperidine 496 13K 3,5- DIFLUOROBENZYL BROMIDE(Lancaster)

4-(4-Chloro-phenyl)-3-(3,4- dichloro-benzyloxy)-4-(3,5-difluoro-benzyloxy)- piperidine 514 13L 3-CHLORO-2- FLUOROBENZYL BROMIDE(Lancaster)

4-(3-Chloro-2-fluoro- benzyloxy)-4-(4-chloro- phenyl)-3-(3,4-dichloro-benzyloxy)-piperidine 530 13M 2,3- DIFLUOROBENZYL BROMIDE (Aldrich)

4-(4-Chloro-phenyl)-3-(3,4- dichloro-benzyloxy)-4-(2,3-difluoro-benzyloxy)- piperidine 514 13N 4-(TRIFLUORO- METHYL)BENZYLBROMIDE (Aldrich)

4-(4-Chloro-phenyl)-3-(3,4- dichloro-benzyloxy)-4-(4-trifluoromethyl-benzyloxy)- piperidine 546 13O 3-FLUOROBENZYL BROMIDE(Aldrich)

4-(4-Chloro-phenyl)-3-(3,4- dichloro-benzyloxy)-4-(3-fluoro-benzyloxy)-piperidine 496 13P ALPHA-BROMO-M- TOLUNITRILE(Aldrich)

3-[4-(4-Chloro-phenyl)-3- (3,4-dichloro-benzyloxy)-piperidin-4-yloxymethyl]- benzonitrile 503 13Q 2-CHLOROBENZYL BROMIDE(Aldrich)

4-(2-Chloro-benzyloxy)-4- (4-chloro-phenyl)-3-(3,4- dichloro-benzyloxy)-piperidine 512 13R 4-METHYLBENZYL BROMIDE (Fluka)

4-(4-Chloro-phenyl)-3-(3,4- dichloro-benzyloxy)-4-(4- methyl-benzyloxy)-piperidine 492

Example 14 Resin-bound cis-[rac]-4-(4-Chloro-phenyl)-piperidine-3,4-diol

This resin-bound compound was prepared fromcis-[rac]-4-(4-chlorophenyl)-3,4-dihydroxypiperidine-1-carboxylic acidtert-butyl ester (Example 1) following the procedure used in Example 6and 7.

Example 15cis-[rac]-4-(4-Chloro-phenyl)-3,4-bis-(2,4-difluoro-benzyloxy)-piperidine

To a suspension of resin-bound 4-(4-Chloro-phenyl)-piperidine-3,4-diol(Example 14, 200 mg, 0.192 mmol, loading capacity: 0.96 mmol/g) and2,4-difluorobenzyl bromide (Lancaster, 1.54 mmol) in 4:1 THF:DMFsolution (2 mL) was added potassium t-butoxide (0.77 M in THF; 1 mL,0.77 mmol). After stirring at room temperature overnight, the resin wasfiltered and washed successively with N,N-dimethylformamide,tetrahydrofuran, methanol, dichloromethane, and diethyl ether. The resinwas dried at 40° C./high vacuum overnight. 1-Chloroethyl chloroformate(0.2 mL, 1.9 mmol) was added to the resin in 1,2-dichloroethane (2 mL).After shaking 4 hours at room temperature, the resin was filtered offand washed with 1,2-dichloroethane (3×2 mL). The filtrate was evaporatedin vacuo. Dry methanol (2 mL) was added to the residue and the solutionwas heated at 60° C. for 3 hours. The solution was evaporated in vacuoto provide the desired product. Mass spectrum (ES) M⁺=480.

Example 16cis-[rac]-4-(4-Chloro-phenyl)-3,4-bis-(3-nitro-benzyloxy)-piperidine

cis-[rac]-4-(4-Chloro-phenyl)-3,4-bis-(3-nitro-benzyloxy)-piperidine wasprepared from resin-bound 4-(4-Chloro-phenyl)-piperidine-3,4-diol(Example 14) and 3-nitrobenzyl bromide (Lancaster) following theprocedure used in Example 15. Mass spectrum (ES) M⁺=498.

Example 17cis-[rac]-1-[4-Benzyloxy-4-(4-chloro-phenyl)-3-substituted-piperidin-1-yl]-ethanoneLibrary:

General procedure

A mixture of 4,4-[benzyloxy-(4-chlorophenyl)]-3-aryloxypiperidine(Example 8, 0.012 mmol), polymer-supported BEMP (10 mg, 0.023 mmol,loading capacity: 2.3 mmol/g from Fluka Inc.), and acetyl chloride (0.01mL, 0.14 mmol) in tetrahydrofuran (1 mL) was shaken at room temperatureovernight. The resin was filtered and washed successively with CH₂Cl₂,and MeOH. The filtrate was evaporated in vacuo to provide the desiredproduct.

In the manner described above, the following compounds were prepared.Mass Spectrum Example Starting Material Product Nomenclature (ES) 17AExample 8G

1-[4-Benzyloxy-4-(4-chloro- phenyl)-3-(2,4-difluoro-benzyloxy)-piperidin-1-yl]- ethanone 486 17B Example 8F

1-[4-Benzyloxy-3-(3-bromo- benzyloxy)-4-(4-chloro-phenyl)-piperidin-1-yl]- ethanone 530 17C Example 8H

1-[4-Benzyloxy-3-(2-chloro-4- fluoro-benzyloxy)-4-(4-chloro-phenyl)-piperidin-1-yl]- ethanone 502 17D Example 8D

1-[4-Benzyloxy-4-(4-chloro- phenyl)-3-(3,5-difluoro-benzyloxy)-piperidin-1-yl]- ethanone 486 17E Example 8K

1-[4-Benzyloxy-3-(3-chloro-2- fluoro-benzyloxy)-4-(4-chloro-phenyl)-piperidin-1-yl]- ethanone 502 17F Example 4

1-[4-Benzyloxy-4-(4-chloro- phenyl)-3-(3,4-dichloro-benzyloxy)-piperidin-1-yl]- ethanone 518 17G Example 8O

1-[4-Benzyloxy-4-(4-chloro- phenyl)-3-(4-fluoro-benzyloxy)-piperidin-1-yl]- ethanone 468 17H Example 8P

1-[4-Benzyloxy-3-(4-bromo- benzyloxy)-4-(4-chloro-phenyl)-piperidin-1-yl]- ethanone 530 17I Example 8Q

1-[4-Benzyloxy-4-(4-chloro- phenyl)-3-(3-fluoro-benzyloxy)-piperidin-1-yl]- ethanone 468 17J Example 8S

3-[1-Acetyl-4-benzyloxy-4-(4- chloro-phenyl)-piperidin-3-yloxymethyl]-benzonitrile 475 17K Example 8B

1-[4-Benzyloxy-4-(4-chloro- phenyl)-3-(2,6-difluoro-benzyloxy)-piperidin-1-yl]- ethanone 486 17L Example 8E

1-[4-Benzyloxy-4-(4-chloro- phenyl)-3-(3-nitro-benzyloxy-piperidin-1-yl]-ethanone 495 17M Example 8Ac

1-[4-Benzyloxy-4-(4-chloro- phenyl)-3-(2,3,4-trifluoro-benzyloxy)-piperidin-1-yl]- ethanone 504 17N Example 13J

1-[4-(4-Chloro-phenyl)-3-(3,4- dichloro-benzyloxy)-4-(2-fluoro-benzyloxy)-piperidin-1- yl]-ethanone 538

Example 18cis-[rac]-1-[4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,3,4-trifluoro-benzyloxy)-piperidin-1-yl]-propan-1-one

cis-[rac]-1-[4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,3,4-trifluoro-benzyloxy)-piperidin-1-yl]-propan-1-onewas prepared from4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,3,4-trifluoro-benzyloxy)-piperidine(Example 8Ad) and propionyl chloride (Aldrich) following the procedureused in Example 17. Mass spectrum (ES) M⁺=518.

Example 19cis-[rac]-1-[4-Benzyloxy-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-piperidin-1-yl]-propan-1-one

cis-[rac]-1-[4-Benzyloxy-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-piperidin-1-yl]-propan-1-onewas prepared fromcis-[rac]-4-(benzyloxy)-4-(4-chlorophenyl)-3-(3,4-dichlorobenzyloxy)-piperidine(Example 4) following the procedure used in Example 18. Mass spectrum(ES) M⁺=533.

Example 20 Resin-boundcis-[rac]-4-benzyloxy-4-(4-fluoro-phenyl)-piperidin-3-ol

This resin-bound compound was prepared from4-(4-fluorophenyl)-1,2,3,6-tetrahydropyridine hydrochloride (Acros)following the procedure used in Examples 1, 5, 6, and 7.

Example 21cis-[rac]-4-Benzyloxy-3-(4-bromo-benzyloxy)-4-(4-fluoro-phenyl)-piperidine

cis-[rac]-4-Benzyloxy-3-(4-bromo-benzyloxy)-4-(4-fluoro-phenyl)-piperidinewas prepared from resin-boundcis-[rac]-4-benzyloxy-4-(4-fluoro-phenyl)-piperidin-3-ol (Example 20)and 4-bromobenzyl bromide (Aldrich) following the procedure used inExample 8. Mass spectrum (ES) MH⁺=471.

Example 22cis-[rac]-4-Benzyloxy-4-(4-fluoro-phenyl)-3-pentyloxy-piperidine

cis-[rac]-4-Benzyloxy-4-(4-fluoro-phenyl)-3-pentyloxy-piperidine wasprepared from resin-boundcis-[rac]-4-benzyloxy-4-(4-fluoro-phenyl)-piperidin-3-ol (Example 20)and 1-iodopentane (Aldrich) following the procedure used in Example 8.Mass spectrum (ES) MH⁺=372.

Example 23cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-1-ethyl-piperidine

A mixture of4-benzyloxy-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-piperidine(Example 4, 0.01 mmol), polymer-supported BEMP (6.5 mg, 0.015 mmol,loading capacity: 2.3 mmol/g from Fluka Inc.), iodoethane (Aldrich,0.015 mmol) in tetrahydrofuran (1 mL) was shaken at room temperatureovernight. The resin was filtered and washed successively with CH₂Cl₂,and MeOH. The filtrate was evaporated in vacuo to provide the desiredproduct. Mass spectrum (ES) MH⁺=506.

Example 24cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-1-propyl-piperidine

cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-1-propyl-piperidinewas prepared from4-benzyloxy-4-(4-chloro-phenyl)-3-(3,4-dichloro-benzyloxy)-piperidine(Example 4) and 1-iodopropane (Aldrich) following the procedure used inExample 23. Mass spectrum (ES) M⁺=519.

Example 25cis-[rac]-3-[4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,3,4-trifluoro-benzyloxy)-piperidin-1-yl]-propane-1,2-diol

A mixture of4-benzyloxy-4-(4-chloro-phenyl)-3-(2,3,4-trifluoro-benzyloxy)-piperidine(Example 8Ac, 6 mg, 0.013 mmol), polymer-supported BEMP (10 mg, 0.023mmol, loading capacity: 2.3 mmol/g from Fluka Inc.), allyl iodide(Aldrich, 3 uL, 0.003 mmol) in tetrahydrofuran (1 mL) was shaken at roomtemperature for 2 hours. The resin was filtered and washed successivelywith CH₂Cl₂, and MeOH. The filtrate was evaporated in vacuo. Withoutpurification, the residue was dissolved in 9:1 acetone/water solution (1mL). To the solution was added osmium tetroxide (Aldrich, 10 uL, 0.008mmol) and 4-methylmorpholine N-oxide (Aldrich, 12 mg, 0.1 mmol). Themixture was stirred overnight and Na₂SO₃ was added. After stirring for 2hours, the mixture was filtered through a silica gel pad. The filtratewas evaporated in vacuo to provide the desired product. Mass spectrum(ES) M⁺=536.

Example 26cis-[rac]-3-[4-Benzyloxy-3-(4-bromo-benzyloxy)-4-(4-chloro-phenyl)-piperidin-1-yl]-propane-1,2-diol

This compound was prepared from4-benzyloxy-3-(4-bromo-benzyloxy)-4-(4-chloro-phenyl)-piperidine(Example 8P) followed the procedure used in Example 25. Mass spectrum(ES) MH⁺=562.

Example 27cis-[rac]-3-[4-Benzyloxy-4-(4-chloro-phenyl)-3-(2,3,4-trifluoro-benzyloxy)-piperidin-1-yl]-methaneSulfonyl

To a solution of4-benzyloxy-4-(4-chloro-phenyl)-3-(2,3,4-trifluoro-benzyloxy)-piperidine(Example 8Ac, 4 mg, 0.008 mmol) and triethylamine (6 uL, 0.08 mmol) indichloromethane (0.5 mL) at 0° C. was added dropwise methanesulfonylchloride (Aldrich, 2.5 uL, 0.015 mmol). After stirring for 2 hours, themixture was filtered through an amino silica gel pad (Silicycle). Thefiltrate was evaporated in vacuo to provide the desired product. Massspectrum (ES) MH⁺=541.

Example 28 In Vitro Activity Assay

The ability of the substituted piperidine compounds of the invention toinhibit the interaction between p53 and MDM2 proteins was measured by anELISA (Enzyme-Linked Immuno Sorbent Assay) in which recombinantGST-tagged MDM2 binds to a peptide that resembles the MDM2-interactingregion of p53 (Bottger et al., J. Mol. Bio. 1997, Vol. 269, pgs.744-756). This peptide is immobilized to the surface of a 96 well platevia N-terminal biotin, which binds to streptavidin-coated wells. MDM2 isadded to each well in the presence of anti-MDM2 mouse monoclonalantibody (SMP-14, Santa Cruz Biotech). After removal of the unbound MDM2protein, a peroxydase-linked secondary antibody (anti-mouse IgG, RocheMolecular Biochemicals) and the amount of peptide-bound MDM2 isdetermined colorimetrically by the addition of a peroxydase substrate(MTB Microwell Peroxydase Substrate System, Kirkegaard & Perry Labs).

Test plates were prepared by coating with streptavidin (5 mg/ml in PBS)for 2 hours followed by a PBS (phosphate-buffered saline) wash andovernight blocking with 150 μl of blocking buffer containing 2 mg/mlbovine serum albumin (Sigma) and 0.05% Tween 20 (Sigma) in PBS at 4° C.Biotinylated peptide (1 PM) is added to each well in 50 μl of blockingbuffer and washed extensively after a 1-hour incubation. Test compoundswere diluted in a separate 96 well plate and added in triplicate to acompound incubation plate containing a mix of the MDM2 protein andanti-MDM2 antibody. After 20 minutes incubation, the content of theplate is transferred to the test plate and incubated for an additional 1hour. The secondary anti-mouse IgG antibody is added to the test platepreceded and followed by a triple wash with 0.05% Tween 20 in PBS.Finally, peroxydase substrate is added to each well and the absorptionwas read using a plate reader (MR7000, Dynatech) at 45° nm. Theinhibitory activity of the test compounds was measured as a percentageof the bound MDM2 in treated vs. untreated wells and IC₅₀ wascalculated.

The inhibitory activity (IC₅₀) of the compounds prepared in the examplesabove, and represented by formula (I) or (II), is in the range of 3 μMto 100 μM.

While a number of embodiments of this invention have been represented,it is apparent that the basic construction can be altered to provideother embodiments that utilize the invention without departing from thespirit and scope of the invention. All such modifications and variationsare intended to be included within the scope of the invention as definedin the appended claims rather than the specific embodiments that havebeen presented by way of example.

1. A compound represented by formula (II):

wherein n is an integer from 1 to 2; X is halogen; R₁ is selected fromthe group consisting of hydrogen, carbonyl, sulfonyl, lower alkyl, andlower alkyl substituted by carbonyl, sulfonyl, or hydroxy; and R₁₂ isselected from the group consisting of alkyl and alkenyl having from 1 toabout 5 carbon atoms; or a pharmaceutically acceptable salt thereof. 2.The compound of claim 1, wherein n is
 1. 3. The compound of claim 1,wherein X is chloro.
 4. The compound of claim 1, wherein X is a parasubstituent.
 5. The compound of claim 1, wherein R₁ is selected from thegroup consisting of hydrogen, —CH₂CH₃, —CH₂CH₂CH₃, —COCH₃, —COCH₂CH₃,—CH₂CHOHCH₂OH, and —SO₂CH₃.
 6. The compound of claim 1, wherein R₁₂ isselected from the group consisting of —(CH₂)₃CH₃, —(CH₂)₄CH₃,—CH₂CH═CHCH₃, and —CH₂CH═CH CH₂CH₃.
 7. The compound according to claim1, wherein, the compound is selected from the group consisting of:cis-[rac]-4-Benzyloxy-4-(4-fluoro-phenyl)-3-butyloxy-piperidine;cis-[rac]-4-Benzyloxy-4-(4-fluoro-phenyl)-3-pentyloxy-piperidine;cis-[rac]-4-Benzyloxy-4-(4-fluoro-phenyl)-3-(but-2-en)yloxy-piperidine;andcis-[rac]-4-Benzyloxy-4-(4-fluoro-phenyl)-3-(pent-2-enyl)oxy-piperidine.8. The compound according to claim 1, wherein, the compound is selectedfrom the group consisting of:cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-butyloxy-piperidine;cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-pentyloxy-piperidine;cis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(but-2-en)yloxy-piperidine;andcis-[rac]-4-Benzyloxy-4-(4-chloro-phenyl)-3-(pent-2-enyl)oxy-piperidine.9. A pharmaceutical composition comprising a therapeutically effectiveamount of a compound of claim 1 and a pharmaceutically acceptablecarrier or excipient.
 10. A method for treating cancer comprisingadministering to a patient in need of such treatment a therapeuticallyeffective amount of a compound of claim
 1. 11. The method of claim 10,wherein the cancer is breast or colon cancer.